Glenmark - The Purbottar

18 Jun

Glenmark launches Indacaterol + Mometasone FDC for Asthma

Business Correspondent0 CommentsBusiness, Health, IndiaGlenmark, ndacaterol + Mometasone

Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily. Alok Malik, Group Vice-President & Head, India Formulations, Glenmark Pharmaceuticals Limited, said, “We are proud to introduce this novel fixed-dose combination Indamet, which is the first…

02 Jun

Glenmark concludes Hypertension Awareness Month

Business Correspondent0 CommentsBusiness, IndiaGlenmark, hypertension

Glenmark Pharmaceuticals Limited (Glenmark) marked May as the Hypertension Awareness Month. Glenmark partnered with more 18,000 healthcare professionals (HCPs) from more than 8000 hospitals and clinics in 50 cities across the country and organized more than 110 public awareness rallies and 8000 screening camps to create mass awareness around Hypertension (High Blood Pressure). The rallies comprised a detailed session by an HCP on the signs, symptoms as well as preventive measures around Hypertension; and were followed by screening camps for the general public. Through this initiative, the company was able to spread awareness amongst more than 2 lakh adults. Being…

27 May

Glenmark launches “Hello Skin” – India’s first Whatsapp based chatbot to help patients suffering from fungal infections

Business Correspondent0 CommentsBusiness, India“Hello Skin”, Glenmark

An innovation-led global pharmaceutical company Glenmark Pharmaceuticals Ltd has developed an digital patient education tool - “Hello Skin” in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) to help patients suffering from Dermatophytosis (Ring Worm or Tinea) in India. It is the first Whatsapp based chatbot which helps patients in not only with daily pill reminders but also in creating disease awareness and provides skincare tips to patients suffering from Ring Worm. It will be available in 6 different regional languages including Hindi and English, enabling better patient compliance to the technology. The recent prevalence of Dermatophytosis…

01 May

Glenmark launches First FDC Drug in India

Business Correspondent0 CommentsBusiness, IndiaFDC Drug, Glenmark

An innovation-driven global pharmaceutical company Glenmark Pharmaceuticals Limited has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin with Pioglitazone. This is the only available brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name ZitaPlusPio which contains Teneligliptin (20 mg) + Pioglitazone (15 mg) to be taken once a day. Glenmark is the first company in India to market the innovative FDC of Teneligliptin+ Pioglitazone which is approved by the Drug Controller General of India. It will be useful for patients who…

14 Feb

Glenmark launched Nitric Oxide Nasal Spray (FabiSpray®) in India

editor0 CommentsBusiness, Health, IndiaGlenmark, Nasal Spray

A worldwide, advancement driven drug organization Glenmark Pharmaceuticals Limited and Canadian drug organization SaNOtize Research and Development Corporation declared send off of its Nitric Oxide Nasal Spray under the brand name FabiSpray® in India for the treatment of grown-up patients with COVID-19 who have high gamble of movement of the sickness. Glenmark prior got assembling and advertising endorsement from the Drugs Controller General of India (DCGI) for NONS as a feature of the sped up endorsement process. FabiSpray®, Nitric Oxide Nasal Spray is intended to kill the COVID-19 infection in the upper aviation routes. Progressively ease 3 preliminary in India…

27 Oct

Glenmark launch Remogliflozin + Vildagliptin + Metforminfixed dose combination

editor0 CommentsBusinessGlenmark

Glenmark Pharmaceuticals Limited (Glenmark), has launched a fixed dose combination (FDC) of its novel, patent protected, globally researched Sodium Glucose Co-Transporter Inhibitor(SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor)– Vildagliptin, with Metformin(first-line medication for the treatment of type 2diabetes).This fixed drug combination is indicated for the management of Type 2 diabetes. The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo MV and Remozen…

06 May

GLENMARK SETS UP DEDICATED FABIFLU WEBPAGE & HELPLINE

editor0 CommentsHealthFabiFlu, Favipiravir tablet, Glenmark

Glenmark Pharmaceuticals has recently announced that they have begun work to increase Favipiravir tablet (brand name FabiFlu) production in the country. The drug firm stated that their production capabilities have been in increased to ensure the antiviral drug’s availability in the market. The company also set up a dedicated FabiFlu toll free helpline 18002666650 and a dedicated webpage with a list of stockists for across the country http://glenmarkpharma.com/fabiflu-availability This website is updated once every 24 hours.

04 May

Glenmark launches Ryaltris-AZ

editor0 CommentsBusinessGlenmark, rysaltris

Glenmark Pharmaceuticals Limited announced the launch of Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. Glenmark is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasonefuroate 50 mcg + Azelastine 140 mcg.While the average cost of therapy of top 10 existing brands of the similar drug category is Rs. 365, Glenmark’s Ryaltris-AZ nasal spray has been launched at a breakthrough price of Rs.…

27 Apr

Glenmark’s Ryaltris nasal spray

editor0 CommentsHealthGlenmark, Ryaltris

Glenmark Pharmaceuticals Limited is concluding the final phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK. Glenmark will commercialise Ryaltris on its own in select markets. In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark. Ryaltris, developed by Glenmark, is…

04 Jan

Glenmark and Menarini’s agreement for Ryaltris Nasal Spray

editor0 CommentsBusinessGlenmark

Glenmark Pharmaceuticals Limited’s (Glenmark) Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris across 33 countries in Europe, including the Balkan region. Ryaltris, developed by Glenmark, is a novel fixed-dose combination nasal spray of anti-histamine and asteroid, indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these markets. Menarini will be responsible for the scientific information…